Thank you for Subscribing to Apac CIO Outlook Weekly Brief
Novotech: World-Class CRO Services Opens Asia-Pacific for Biopharma Companies
Like drug marketing strategies, the impact of key opinion leaders (KOLs) is a global phenomenon. Walking a dangerous line with key opinion leaders, pharmaceutical companies have engaged these leaders in an ever-broader range of assignments—from clinical-trials consulting, expert speaking, and more. In such an environment coupled with extreme competition and diversified regulatory norms in the clinical trial industry, the pharma and life science companies in the Asia-Pacific region are on the lookout for employing solid partnerships that can provide them with prime access to key opinion leaders and optimize their clinical research programs. Added to that, with a burgeoning investment of capital in the biotech sector, making the right decisions at the right time becomes the critical aspect for firms to deliver successful business outcomes in their programs. Novotech, the Asia- Pacific contract research organization (CRO) is keen to aid the industry in achieving the same, with its deep clinical expertise of over 22 years in the region. With the rise of heterogeneous regulatory regimes in different countries, Novotech has been instrumental in the success of hundreds of phase I-IV clinical trials. Novotech is a regional CRO with rich country-specific experience and strong relationships with local KOLs and institutions.
“Novotech is a full-service CRO, with an exceptional business model and understanding of the regulatory and clinical research implementation complexities across the Asia- Pacific region,” says Dr. John Moller, CEO of Novotech.
Novotech is a full-service CRO, with an exceptional business model and understanding of the regulatory and clinical research implementation complexities across the Asia-Pacific region
Under the recent ownership of TPG Capital Asia, the company continues its rapid growth and has recently acquired Clinical Network Services (CNS), an Australian CRO specialist, further enhancing its position as a world-class midsize CRO.
Novotech offers an exclusive suite of consultative services to its clients, which includes elements like feasibility, clinical services, project management, data management, statistical services, quality assurance, and a full range of medical services, as well as commercialization services. Moreover, the company also directs its focus on serving the complex needs of the biotech sector and to address the diverse regulatory norms across the Asian countries. Novotech’s recent acquisition of CNS has enabled them to add an essential ‘BioDesk’ capability to its services. “BioDesk capability allows users access to an early stage product development advice including toxicology and FDA/EMA regulatory consulting to get their drug into the market faster and also involves all the multi-functional aspects required in their clinical development,” continues Moller.
From an APAC-centric standpoint, Novotech features access to the best key opinion leaders and has a reputation for delivering guaranteed clinical trial approvals. The company also offers clients global technology standards with systems like LiveData, Oracle Forms, and the recent multi-million dollar investment in Oracle’s cloud-based CTMS systems, allowing them to achieve scalability coupled with real-time updates to the latest versions quickly.
From a recent survey conducted during the J.P. Morgan week in San Francisco, clinical data quality was considered as the leading tailwind for 2019. This is especially true given the increasing complexity of trials and the surge of adaptive designs in clinical studies. There is an increasing investment in upfront clinical development strategy, including the use of carefully designed adaptive protocols. Novotech proposes an efficient approach to clinical trial design to get the greatest impact in containing the escalating cost of drug development.
Exclusively committed to the APAC region, the company is revving up the recruitment of high-quality posts in Asia.